Arvinas (NASDAQ:ARVN) & Anika Therapeutics (NASDAQ:ANIK) Head-To-Head Survey

Anika Therapeutics (NASDAQ:ANIK) and Arvinas (NASDAQ:ARVN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, risk, earnings, valuation, institutional ownership and dividends.

Profitability

This table compares Anika Therapeutics and Arvinas’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Anika Therapeutics	-3.14%	0.20%	0.15%
Arvinas	2.94%	1.91%	1.29%

Earnings and Valuation

This table compares Anika Therapeutics and Arvinas”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anika Therapeutics	$120.65 million	2.31	-$10.88 million	($0.27)	-77.07
Arvinas	$262.60 million	2.31	-$80.80 million	$0.10	93.90

Anika Therapeutics has higher earnings, but lower revenue than Arvinas. Anika Therapeutics is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Anika Therapeutics has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500. Comparatively, Arvinas has a beta of 1.75, suggesting that its share price is 75% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Anika Therapeutics and Arvinas, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anika Therapeutics	1	0	2	1	2.75
Arvinas	2	4	5	0	2.27

Anika Therapeutics currently has a consensus price target of $21.00, indicating a potential upside of 0.91%. Arvinas has a consensus price target of $14.17, indicating a potential upside of 50.87%. Given Arvinas’ higher possible upside, analysts clearly believe Arvinas is more favorable than Anika Therapeutics.

Insider and Institutional Ownership

91.5% of Anika Therapeutics shares are owned by institutional investors. Comparatively, 95.2% of Arvinas shares are owned by institutional investors. 12.1% of Anika Therapeutics shares are owned by insiders. Comparatively, 7.3% of Arvinas shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Arvinas beats Anika Therapeutics on 10 of the 15 factors compared between the two stocks.

About Anika Therapeutics

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company’s joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

About Arvinas

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.